PMID- 28616768
OWN - NLM
STAT- MEDLINE
DCOM- 20180423
LR  - 20220321
IS  - 1573-7217 (Electronic)
IS  - 0167-6806 (Linking)
VI  - 165
IP  - 2
DP  - 2017 Sep
TI  - Antitumor activity and safety profile of weekly carboplatin plus paclitaxel in 
      metastatic breast cancer: a ten-year, monocentric, retrospective study.
PG  - 365-373
LID - 10.1007/s10549-017-4336-z [doi]
AB  - BACKGROUND: Taxanes are a mainstay in the treatment of metastatic breast cancer 
      (mBC). Combination chemotherapy, including platinum-taxens doublets, can improve 
      tumor responses and progression-free survival (PFS), but is associated with more 
      toxicities and an uncertain benefit in terms of overall survival (OS). METHODS: 
      We performed a retrospective study on 274 consecutive patients with mBC treated 
      at the Division of Medical Oncology of Fondazione IRCCS Istituto Nazionale 
      Tumori, Milan, Italy, during the decade 2007-2016 with the combination of 
      carboplatin AUC 2 plus paclitaxel 80 mg/m(2), both given on days 1 and 8 in every 
      21-day cycle. RESULTS: 264 patients were evaluable for treatment safety and 
      activity. The objective response rate (ORR) was 44.7%. Median PFS and OS were 8.6 
      and 23.7 months, respectively. Triple-negative breast cancer (TNBC) patients had 
      significantly lower PFS and OS times compared to other biology groups. At 
      multivariable analysis, previous exposure to taxanes, HR-positive HER2-negative 
      biology, a higher number of metastatic sites, and de novo metastatic disease at 
      diagnosis were associated with reduced PFS, while receiving maintenance therapy 
      correlated with improved PFS. Overall, the treatment was quite well tolerated, 
      with 10.2% of patients discontinuing one or both drugs because of adverse events 
      (AEs). G3-G4 neutropenia occurred in 16.8% of patients, while the incidence of 
      febrile neutropenia was 2.3%. CONCLUSIONS: Weekly carboplatin-paclitaxel regimen 
      is active and well tolerated in mBC treatment. Prospective studies should be 
      conducted to compare its efficacy and tolerability with standard single-agent 
      paclitaxel or docetaxel treatment schedules, as well as with more recent 
      combination regimens.
FAU - Vernieri, Claudio
AU  - Vernieri C
AUID- ORCID: 0000-0003-1577-8176
AD  - Medical Oncology Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Via 
      Venezian 1, 20133, Milan, Italy. claudio.vernieri@istitutotumori.mi.it.
AD  - Fondazione Istituto FIRC di Oncologia Molecolare (IFOM), Via Adamello 16, Milan, 
      Italy. claudio.vernieri@istitutotumori.mi.it.
FAU - Milano, Monica
AU  - Milano M
AD  - Medical Oncology Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Via 
      Venezian 1, 20133, Milan, Italy.
FAU - Mennitto, Alessia
AU  - Mennitto A
AD  - Medical Oncology Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Via 
      Venezian 1, 20133, Milan, Italy.
FAU - Maggi, Claudia
AU  - Maggi C
AD  - Medical Oncology Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Via 
      Venezian 1, 20133, Milan, Italy.
FAU - Ferrari, Benvenuto
AU  - Ferrari B
AD  - Medical Oncology Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Via 
      Venezian 1, 20133, Milan, Italy.
FAU - Rinaldi, Lucia
AU  - Rinaldi L
AD  - Medical Oncology Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Via 
      Venezian 1, 20133, Milan, Italy.
FAU - Mennitto, Roberta
AU  - Mennitto R
AD  - Medical Oncology Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Via 
      Venezian 1, 20133, Milan, Italy.
FAU - Stefanetti, Claudia
AU  - Stefanetti C
AD  - Medical Oncology Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Via 
      Venezian 1, 20133, Milan, Italy.
FAU - Re, Barbara
AU  - Re B
AD  - SC Pharmacy, Fondazione IRCCS Istituto Nazionale dei Tumori, Via Venezian 1, 
      20133, Milan, Italy.
FAU - Mariani, Gabriella
AU  - Mariani G
AD  - Medical Oncology Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Via 
      Venezian 1, 20133, Milan, Italy.
FAU - Bianchi, Giulia
AU  - Bianchi G
AD  - Medical Oncology Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Via 
      Venezian 1, 20133, Milan, Italy.
FAU - Capri, Giuseppe
AU  - Capri G
AD  - Medical Oncology Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Via 
      Venezian 1, 20133, Milan, Italy.
FAU - de Braud, Filippo
AU  - de Braud F
AD  - Medical Oncology Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Via 
      Venezian 1, 20133, Milan, Italy.
AD  - Universita' degli Studi di Milano, Milan, Italy.
LA  - eng
PT  - Journal Article
DEP - 20170614
PL  - Netherlands
TA  - Breast Cancer Res Treat
JT  - Breast cancer research and treatment
JID - 8111104
RN  - 0 (Biomarkers, Tumor)
RN  - BG3F62OND5 (Carboplatin)
RN  - P88XT4IS4D (Paclitaxel)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Antineoplastic Combined Chemotherapy Protocols/adverse effects/*therapeutic use
MH  - Biomarkers, Tumor
MH  - Breast Neoplasms/*drug therapy/mortality/*pathology
MH  - Carboplatin/administration & dosage
MH  - Disease Progression
MH  - Drug Administration Schedule
MH  - Female
MH  - Humans
MH  - Kaplan-Meier Estimate
MH  - Middle Aged
MH  - Neoplasm Metastasis
MH  - Neoplasm Staging
MH  - Paclitaxel/administration & dosage
MH  - Prognosis
MH  - Proportional Hazards Models
MH  - Retrospective Studies
MH  - Treatment Outcome
OTO - NOTNLM
OT  - Combination chemotherapy
OT  - HER2-positive breast cancer
OT  - Hormone receptor-positive breast cancer
OT  - Metastatic breast cancer
OT  - Triple-negative breast cancer
OT  - Weekly carboplatin-paclitaxel
EDAT- 2017/06/16 06:00
MHDA- 2018/04/24 06:00
CRDT- 2017/06/16 06:00
PHST- 2017/06/05 00:00 [received]
PHST- 2017/06/08 00:00 [accepted]
PHST- 2017/06/16 06:00 [pubmed]
PHST- 2018/04/24 06:00 [medline]
PHST- 2017/06/16 06:00 [entrez]
AID - 10.1007/s10549-017-4336-z [pii]
AID - 10.1007/s10549-017-4336-z [doi]
PST - ppublish
SO  - Breast Cancer Res Treat. 2017 Sep;165(2):365-373. doi: 10.1007/s10549-017-4336-z. 
      Epub 2017 Jun 14.